CHARACTERIZATION OF BIOACTIVE COMPOUNDS FROM MARINE ACTINOMYCETES ANTAGONISTIC TO URINARY TRACT BACTERIAL PATHOGENS

Main Article Content

P. DEEPA MATHEW
K. SUKESH

Abstract

The development of multi drug resistant uropathogens is a big threat to human race. Infections with multidrug- resistant bacteria are hard to treat. The present study Characterization of bioactive compounds from marine actinomycetes antagonistic to urinary tract bacterial pathogens is aimed to prove that marine actinomycetes have some bioactive compounds which are antagonistic to multi drug resistant uropathogens. In this study there were 14 different urine samples which were collected from urinary tract infection (UTI) suspected patients and from these specimens five uropathogens were isolated. Thirty seven (37) marine actinomycetes were isolated from various marine samples that were collected from different stations of Kovalam coastal region, part of Arabian Sea on the western coast of India. The isolated colonies were studied on their morphological characteristics. These diverse colonies were observed and which indicated the potential diversity of the actinomycetes that had been isolated from various sources. The antagonistic activity studies showed that among the 37 marine actinomycetes isolates 10 isolates showed significant antagonism against all the five test organisms that were cultured including Escherichia coli, Klebsiella sp., Pseudomonas sp., Enterococcus sp., Proteus sp. in the primary screening. The isolate KVSD9 showed maximum inhibitory activity against Escherichia coli (18mm). The result was consistent on both well diffusion and disc diffusion methods. Similarly KVSD4 showed maximum activity against Klebsiella sp. KVSD35 showed maximum activity against Pseudomonas sp. in well diffusion assay. But in disc diffusion method KVSD2 was the most potent strain against Pseudomonas sp. Against Enterococcus sp. KVSD9 showed the highest antagonistic activity in both the secondary assays followed by KVSD2. KVSD4 was the most potent isolate against Proteus sp. in both disc and well diffusion methods.

Keywords:
Multi drug resistant (MDR), marine actinomycetes, antagonism, urinary tract infection (UTI)

Article Details

How to Cite
MATHEW, P. D., & SUKESH, K. (2021). CHARACTERIZATION OF BIOACTIVE COMPOUNDS FROM MARINE ACTINOMYCETES ANTAGONISTIC TO URINARY TRACT BACTERIAL PATHOGENS. Journal of Basic and Applied Research International, 27(6), 1-16. Retrieved from https://www.ikprress.org/index.php/JOBARI/article/view/6843
Section
Original Research Article

References

Ronald AR, Nicolle LE, Stamm E, Krieger J, Warren J, Schaeffer A, Naber KG, Hooton TM, Johnson J, Chambers S, Andriole V. Urinary tract infection in adults: Research priorities and strategies. Int J antimicrobial agents. 2001;17(4):343-348.

Stamm WE, Norrby SR. Urinary tract infections: Disease panorama and challenges. J. Infect. Dis. 2001;183:S1-4.

Totsika M, Gomes Moriel D, Idris A, A Rogers B, J Wurpel D, Phan MD, L Paterson D, A Schembri M. Uropathogenic Escherichia coli mediated urinary tract infection. Curr. Drug Targets. 2012;13(11):1386-1399.

Barber AE, Norton JP, Spivak AM, Mulvey MA. Urinary tract infections: Current and emerging management strategies. Clin. Infect. Dis. 2013;57(5):719-724.

Pardeshi P. Prevalence of urinary tract infections and current scenario of antibiotic susceptibility pattern of bacteria causing UTI. Indian J Microbiol Res. 2018;5(3):334-338.

Kant S, Lohiya A, Kapil A, Gupta SK. Urinary tract infection among pregnant women at a secondary level hospital in Northern India. Indian J. Public Health. 2017;61(2):118.- 123.

Janifer J, Geethalakshmi S, Satyavani K, Viswanathan V. Prevalence of lower urinary tract infection in South Indian type 2 diabetic subjects. Indian J Nephrol. 2009;19(3):107-111.

Tandogdu Z, Wagenlehner FM. Global epidemiology of urinary tract infections. Curr. Opin. Infect. Dis. 2016;29(1):73-79.

Öztürk R, Murt A. Epidemiology of urological infections: a global burden. World J Urol. 2020;10:1-1.

Hooton TM. Uncomplicated urinary tract infection. New Engl J Med. 2012;366:1028–1037.

Kline KA, Schwartz DJ, Lewis WG, Hultgren SJ, Lewis AL. Immune activation and suppression by group B Streptococcus in a murine model of urinary tract infection. Infect Immun. 2011;79:3588–3595.

Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. Am J Med. 2002;113:14S–19S.

Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: Epidemiology, mechanisms of infection and treatment options. Nat. Rev. Microbiol. 2015;13(5):269-84.

Kostakioti M, Hultgren SJ, Hadjifrangiskou M. Molecular blueprint of uropathogenic Escherichia coli virulence provides clues toward the development of anti-virulence therapeutics. Virulence. 2012;3:592–594.

Trestioreanu AZ, Green H, Paul M, Yaphe J, Leibovici L. Antimicrobial agents for treating uncomplicated urinary tract infection in women. Cochrane Database Syst. Rev. 2010;1-10.

Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. Bmj. 2010;18;340.

World Health Organization. Antimicrobial resistance global report on surveillance 2014. World Health Organization [online]; 2014.
Available:http://www.who.int/drugresistance/documents/surveillancereport/en/

Exner M, Bhattacharya S, Christiansen B, Gebel J, Goroncy-Bermes P, Hartemann P, Heeg P, Ilschner C, Kramer A, Larson E, Merkens W. Antibiotic resistance: What is so special about multidrug-resistant Gram-negative bacteria? GMS Hyg Infect Control. 2017;12.
DOI: 10.3205/dgkh000290 PMID: 28451516; PMCID: PMC5388835.

Castillo UF, Strobel GA, Mullenberg K, Condron MM, Teplow DB, Folgiano V, et al. Munumbicins E-4 and E-5: novel broad-spectrum antibiotics from Streptomyces NRRL 3052. FEMS Microbiol Lett. 2006;255 (2):296–300.

Garrity GM, Bell JA, Lilburn TG. Taxonomic outline of the prokaryotes. Bergey’s manual of systematic bacteriology. New York; 2004.

Chakraborty RD, Chakraborty K, Thilakan B. Isolation and characterization of antagonistic Streptomyces spp. from marine sediments along the southwest coast of India. Ind J Geo-Marine Sci. 2015;44(1).

Rajivgandhi G, Ramachandran G, Maruthupandy M, Saravanakumar S, Manoharan N, Viji R. Antibacterial effect of endophytic actinomycetes from marine algae against multi drug resistant gram negative bacteria. Exam Mar Biol Oceanogr. 2018;1(4):1-8.

Rajan BM, Kannabiran K. Extraction and identification of antibacterial secondary metabolites from marine Streptomyces sp. VITBRK2. Int J Mol Cell Med. 2014;3(3):130-137

Yadav AK, Kumar R, Saikia R, Bora TC, Arora DK. Novel copper resistant and antimicrobial Streptomyces isolated from Bay of Bengal, India. Journal de Mycologie Medicale. 2009;19:234–240.

Wahaab F, Subramaniam K. Bioprospecting marine actinomycetes for multidrug-resistant pathogen control from Rameswaram coastal area, Tamil Nadu, India. Arch Microbiol. 2018;200(1):57-71.

Ramesh S, Mathivanan N. Screening of marine actinomycetes isolated from the Bay of Bengal, India for antimicrobial activity and industrial enzymes. World J Microbiol Biotechnol. 2009; 25:2103–2111.

Solanki R, Khanna M, Lal R. Bioactive compounds from marine actinomycetes. Indian J Microbiol. 2008;48:410–431.

Hong K, Gao AH, Xie QY, Gao H, Zhuang L, Lin HP. Actinomycetes for marine drug discovery isolated from mangrove soils and plants in China. Mar Drugs. 2009;7: 24–44.

Benita MR, Kannabiran K. Antimicrobial activity of Streptomyces albofaciens against methicillin resistant Staphylococcus Aureus and vancomycin resistant enterococcus multi-drug resistant species. Res J Pharm Biol Chem Sci. 2013;4(3):1248–1257